Keywords: serono, discontinues, certain, onercept, canvaxin, development, swiss

Serono discontinues certain onercept and Canvaxin development

Article | 11 April 2005

Swiss biotechnology major Serono says that it has discontinued two Phase III clinical trial programs: onercept (recombinant tumor necrosis factor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing